# A Bioequivalence Study Between Fluticasone and Salmeterol vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade

> **NCT04124094** · PHASE1 · COMPLETED · sponsor: **Respirent Pharmaceuticals Co Ltd.** · enrollment: 36 (actual)

## Conditions studied

- Bioequivalence

## Interventions

- **DRUG:** Test Product (Fluticasone propionate and salmeterol xinafoate inhalation powder/Respirent Pharmaceuticals)
- **DRUG:** Reference Product (SERETIDE DISKUS® 100/50 inhalation powder/GSK)
- **OTHER:** Activated Charcoal suspension

## Key facts

- **NCT ID:** NCT04124094
- **Lead sponsor:** Respirent Pharmaceuticals Co Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-01
- **Primary completion:** 2019-10-25
- **Final completion:** 2020-06-09
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2020-07-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04124094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04124094, "A Bioequivalence Study Between Fluticasone and Salmeterol vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04124094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*